Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

W De Roock, DJ Jonker, F Di Nicolantonio… - Jama, 2010 - jamanetwork.com
Context Patients with metastatic colorectal cancer who have KRAS codon 12–or KRAS
codon 13–mutated tumors are presently excluded from treatment with the anti–epidermal
growth factor receptor monoclonal antibody cetuximab. Objective To test the hypothesis that
KRAS codon 13 mutations are associated with a better outcome after treatment with
cetuximab than observed with other KRAS mutations. Design, Setting, and Patients We
studied the association between KRAS mutation status (p. G13D vs other KRAS mutations) …